Skip to main content

Cruse Michael's Form 4 filing

OnKure Therapeutics, Inc. (OKUR) · filed Aug 26, 2021

Accession no.
0001209191-21-053520
Filed
Aug 26, 2021
Trade date
Aug 25, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction. Open-market purchases total $18.6K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cruse MichaelCIK 0001854179Officer (Senior VP-Corporate Operations)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 25, 2021Common StockPPurchaseAcquired+2,500$7.45F1+$18,6252,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The weighted average purchase price for the transaction was $7.4464. The shares were purchased at a range of prices between $7.425 and $7.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)